» Articles » PMID: 35860171

Blood Metabolic Signatures of Hikikomori, Pathological Social Withdrawal

Overview
Specialty Neurology
Date 2022 Jul 21
PMID 35860171
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A severe form of pathological social withdrawal, 'hikikomori,' has been acknowledged in Japan, spreading worldwide, and becoming a global health issue. The pathophysiology of hikikomori has not been clarified, and its biological traits remain unexplored.

Methods: Drug-free patients with hikikomori ( = 42) and healthy controls ( = 41) were recruited. Psychological assessments for the severity of hikikomori and depression were conducted. Blood biochemical tests and plasma metabolome analysis were performed. Based on the integrated information, machine-learning models were created to discriminate cases of hikikomori from healthy controls, predict hikikomori severity, stratify the cases, and identify metabolic signatures that contribute to each model.

Results: Long-chain acylcarnitine levels were remarkably higher in patients with hikikomori; bilirubin, arginine, ornithine, and serum arginase were significantly different in male patients with hikikomori. The discriminative random forest model was highly performant, exhibiting an area under the ROC curve of 0.854 (confidential interval = 0.648-1.000). To predict hikikomori severity, a partial least squares PLS-regression model was successfully created with high linearity and practical accuracy. In addition, blood serum uric acid and plasma cholesterol esters contributed to the stratification of cases.

Conclusions: These findings reveal the blood metabolic signatures of hikikomori, which are key to elucidating the pathophysiology of hikikomori and also useful as an index for monitoring the treatment course for rehabilitation.

Citing Articles

The flow cytometric analysis of depression focusing on modern-type depression and hikikomori: Exploring the link between subtypes of depression and immunological imbalances.

Matsuo K, Watanabe M, Inamine S, Matsushima T, Kyuragi S, Maeda Y Dialogues Clin Neurosci. 2025; 27(1):13-25.

PMID: 39831784 PMC: 11748865. DOI: 10.1080/19585969.2025.2452842.


Hikikomori: A Society-Bound Syndrome of Severe Social Withdrawal.

Dong B, Li D, Baker G Psychiatry Clin Psychopharmacol. 2024; 32(2):167-173.

PMID: 38764869 PMC: 11099621. DOI: 10.5152/pcp.2022.22429.


Translational chasm and dialogues in clinical neuroscience.

Yatham L, Thibaut F Dialogues Clin Neurosci. 2022; 23(1):1-2.

PMID: 35860176 PMC: 9286733. DOI: 10.1080/19585969.2022.2073566.

References
1.
Rigato I, Ostrow J, Tiribelli C . Bilirubin and the risk of common non-hepatic diseases. Trends Mol Med. 2005; 11(6):277-83. DOI: 10.1016/j.molmed.2005.04.008. View

2.
Miller A, Maletic V, Raison C . Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9):732-41. PMC: 2680424. DOI: 10.1016/j.biopsych.2008.11.029. View

3.
Furukawa T, Streiner D, Azuma H, Higuchi T, Kamijima K, Kanba S . Cross-cultural equivalence in depression assessment: Japan-Europe-North American study. Acta Psychiatr Scand. 2005; 112(4):279-85. DOI: 10.1111/j.1600-0447.2005.00587.x. View

4.
Hamilton M . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6(4):278-96. DOI: 10.1111/j.2044-8260.1967.tb00530.x. View

5.
Kelley M, Choi K, Rajendra J, Craighead W, Rakofsky J, Dunlop B . Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. Biol Psychiatry. 2021; 90(4):236-242. PMC: 8324510. DOI: 10.1016/j.biopsych.2021.02.966. View